{
    "id": 17515,
    "fullName": "NOTCH2 rearrange",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NOTCH2 rearrange indicates an unspecified rearrangement of the NOTCH2 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4853,
        "geneSymbol": "NOTCH2",
        "terms": [
            "NOTCH2",
            "AGS2",
            "HJCYS",
            "hN2"
        ]
    },
    "variant": "rearrange",
    "createDate": "02/01/2016",
    "updateDate": "08/01/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4316,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, triple receptor-negative breast cancer xenograft models harboring NOTCH2 rearrangement were resistant to MRK-003 induced tumor growth inhibition (PMID: 25104330).",
            "molecularProfile": {
                "id": 17811,
                "profileName": "NOTCH2 rearrange"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4320,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 and Taxol (paclitaxel) worked synergistically to inhibit tumor growth in triple receptor-negative breast cancer xenograft models harboring NOTCH2 rearrangement (PMID: 25104330).",
            "molecularProfile": {
                "id": 17811,
                "profileName": "NOTCH2 rearrange"
            },
            "therapy": {
                "id": 3491,
                "therapyName": "MRK-003 + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 17811,
            "profileName": "NOTCH2 rearrange",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17812,
            "profileName": "NOTCH2 rearrange ERBB2 neg ESR1 neg PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}